BioSyent Releases Results for Fourth Quarter and Full Year 2017

BioSyent (TSXV:RX) released today a summary of its financial results for the three and twelve months ended December 31, 2017.

As quoted in the press release:

“BioSyent had a strong finish to 2017 with both our Canadian and International Pharmaceutical businesses posting record quarterly sales in Q4,” commented René Goehrum, President and CEO of BioSyent.  “Overall, 2017 was a year of continued organic growth, with our total sales of $20.8 million growing by 16% year-over-year.  While we continued to shepherd three new products through the regulatory approval process during the year, we maintained a net profit margin of 25%.  Once these new products are approved by Health Canada, they will add to the breadth and diversity of the Company’s product portfolio.  We look forward to the year ahead as we continue to grow our existing brands and strive to bring new, innovative pharmaceutical and healthcare products to market.”

Click here to read the full press release.